AP Biosciences, Inc. AI Stock Analysis
AP Biosciences, Inc. (6945) AI Stock Analysis
AP Biosciences, Inc.
(TPEx:6945)
The score is held down primarily by financial performance: AP Biosciences generates no revenue, posted a NT$444.8 million net loss in 2025 and burns roughly NT$380 million of free cash annually, with equity down 22% in a year and a likely need for additional, potentially dilutive funding. Its main strength is a conservative, almost debt-free balance sheet with NT$1.27 billion of equity, which limits near-term solvency risk. Technicals reinforce caution, with the price below its 20-, 50- and 200-day moving averages and a negative MACD. Valuation adds no support given negative earnings and no dividend. The investment case depends almost entirely on clinical and partnering milestones rather than current financial results.
AP Biosciences, Inc. (6945) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 11.41B
- Dividend Yield
- ―
- Average Volume (3M)
- 386.70K
- Price to Earnings (P/E)
- -20.8
- Beta (1Y)
- 0.77
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 37
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
AP Biosciences, Inc. Business Overview & Revenue Model
Company Description
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candid...
AP Biosciences, Inc. Financial Statement Overview
Summary
AP Biosciences is a pre-revenue clinical-stage biotech with no commercial sales and widening losses — net loss reached NT$444.8 million in 2025 versus NT$187.6 million in 2021 (Income Statement score 13). Cash generation is equally weak, with operating outflow of NT$352.1 million and free cash outflow of NT$377.3 million in 2025 (Cash Flow score 16). The offsetting strength is a nearly debt-free balance sheet (debt-to-equity of just 0.05, equity funding ~93% of assets, Balance Sheet score 60), though equity shrank 22% in one year to NT$1.27 billion and current resources cover only around three years of burn, implying future dilution risk. Modest positives include decelerating loss growth and a slight year-over-year reduction in operating burn.
Income Statement
13Very NegativeBalance Sheet
60NeutralCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 32.25M | 0 | 6.99M |
| Gross Profit | -13.72M | -25.52M | -17.48M | 32.25M | -8.68M | 6.99M |
| EBITDA | -495.00M | -430.86M | -403.61M | -325.51M | -290.07M | -177.86M |
| Net Income | -464.34M | -444.77M | -422.75M | -339.30M | -288.54M | -187.61M |
Balance Sheet | ||||||
| Total Assets | 2.41B | 1.37B | 1.73B | 890.76M | 1.10B | 579.35M |
| Cash, Cash Equivalents and Short-Term Investments | 2.19B | 1.17B | 1.54B | 740.02M | 1.08B | 557.12M |
| Total Debt | 53.73M | 59.51M | 70.91M | 82.08M | 0 | 0 |
| Total Liabilities | 86.64M | 94.22M | 104.38M | 106.65M | 4.52M | 21.15M |
| Stockholders Equity | 2.33B | 1.27B | 1.62B | 784.11M | 1.10B | 558.20M |
Cash Flow | ||||||
| Free Cash Flow | -382.79M | -377.35M | -363.40M | -333.03M | -278.41M | -173.60M |
| Operating Cash Flow | -365.80M | -352.09M | -357.88M | -297.62M | -275.97M | -168.68M |
| Investing Cash Flow | -1.92B | -125.25M | 326.37M | -468.68M | -3.15M | -34.92M |
| Financing Cash Flow | 1.21B | 4.51M | 1.20B | -3.10M | 800.00M | 100.00M |
AP Biosciences, Inc. Peers Comparison
Overall Rating
TW:172071Outperform
TW:657642Neutral- TW:694540Underperform
TW:653539Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1720 | 71Outperform | TWD 10.81B | 10.22 | ― | 3.64% | 4.62% | 9.56% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6576 | 42Neutral | TWD 11.52B | 524.28 | ― | ― | 6.41% | ― |
| TW:6945 | 40Underperform | TWD 11.22B | -20.83 | ― | ― | ― | ― |
| TW:6535 | 39Underperform | TWD 12.33B | -31.94 | ― | ― | -24.84% | 9.15% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6945 | AP Biosciences, Inc. | 115.00 | 1.00 | 0.88% | |
| TW:1720 | Standard Chemical & Pharmaceutical Co. Ltd. | 55.00 | 2.61 | 4.99% | |
| TW:6467 | TAHO Pharmaceuticals Ltd | 246.00 | 70.00 | 39.77% | |
| TW:6535 | LUMOSA THERAPEUTICS CO LTD | 73.50 | -116.50 | -61.32% | |
| TW:6576 | Foresee Pharmaceuticals Co., Ltd. | 73.10 | -4.40 | -5.68% | |
| TW:6748 | ACRO Biomedical Co., Ltd. | 168.50 | 107.65 | 176.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026